Table 2. Guidelines for the prevention... | American Society of Hematology

Table 2.

Guidelines for the prevention of MRBD and treatment of SREs

Drug	Dose	Scheme of administration	Duration
Zoledronate IV^a	4 mg	Monthly for 12 mo; if ≥VGPR after 12 mo consider a 3-mo dose interval.	At least 12 mo. If discontinued reinitiate at biochemical relapse.
Pamidronate IV^a	30 mg	See at zoledronate	See at zoledronate
Denosumab SC^a	120 mg	Monthly	Continuously. If discontinued, administer 1 dose of zoledronate 6 mo after the last dose to prevent rebound effects

Drug	Dose	Scheme of administration	Duration
Zoledronate IV^a	4 mg	Monthly for 12 mo; if ≥VGPR after 12 mo consider a 3-mo dose interval.	At least 12 mo. If discontinued reinitiate at biochemical relapse.
Pamidronate IV^a	30 mg	See at zoledronate	See at zoledronate
Denosumab SC^a	120 mg	Monthly	Continuously. If discontinued, administer 1 dose of zoledronate 6 mo after the last dose to prevent rebound effects

^a

All patients who are treated with bisphosphonates or denosumab should receive calcium and vitamin D supplementation.

Adapted with permission from Terpos et al.³